NCT03413306 is a Phase 3 clinical trial of Eltrombopag in Acquired Aplastic Anemia, sponsored by Federal Research Institute of Pediatric Hematology, Oncology and Immunology.

What drugs are being tested in NCT03413306?

Interventions in NCT03413306: Eltrombopag, IST (ATG + CsA).

What condition does NCT03413306 study?

NCT03413306 studies Acquired Aplastic Anemia.

Is NCT03413306 still recruiting?

NCT03413306 is currently status unknown. Last updated 15 March 2021.

Last reviewed 2021-03-15 · How we verify

NCT03413306

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA

Status unknown Phase 3 Last updated 15 March 2021

What this trial tests

Phase 3 trial testing Eltrombopag in Acquired Aplastic Anemia in 100 participants. Status unknown.

Timeline

10 December 2016

Primary endpoint
20 October 2022

20 October 2022

Quick facts

Lead sponsor	Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	10 December 2016
Primary completion	20 October 2022
Estimated completion	20 October 2022
Sites	1 location across Russia

Drugs / interventions tested

Eltrombopag (ELTROMBOPAG) — full drug profile →
IST (ATG + CsA) — full drug profile →

Conditions studied

Acquired Aplastic Anemia — all drugs for Acquired Aplastic Anemia →

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Who can join

Adults 2 to 18, any sex, with Acquired Aplastic Anemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The analysis of our own clinical data suggests that majority of the hematologic responses observed after the course of h-ATG/CsA is partial, and about 10% tend to have cyclosporine dependence. The aim of the current study is to improve the rate and the quality of hematologic response as well as to prevent delayed complications such as relapse and clonal progression by means of adding eltrombopag to standard immunosuppressive therapy

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Activity of eltrombopag in severe aplastic anemia.
Scheinberg P. · · 2018 · cited 31× · PMID 30425070 · DOI 10.1182/bloodadvances.2018020248
Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia.
Goronkova O, Novichkova G, Salimova T, Kalinina I, et al · · 2023 · cited 24× · PMID 35446936 · DOI 10.1182/bloodadvances.2021006716
Activity of eltrombopag in severe aplastic anemia.
Scheinberg P. · · 2018 · cited 21× · PMID 30504345 · DOI 10.1182/asheducation-2018.1.450

Verify or expand the search:

Other trials of Eltrombopag

Trials testing the same drug.

NCT07189910 — Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP · Phase 4 · not yet recruiting
NCT07113743 — Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease · Phase 1, PHASE2 · enrolling by invitation
NCT07093606 — Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura · NA · recruiting
NCT06345495 — High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly · Phase 2 · recruiting
NCT05653219 — A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia · Phase 3 · active not recruiting

Other Federal Research Institute of Pediatric Hematology, Oncology and Immunology trials

Trials by the same sponsor.

NCT07316595 — Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome · Phase 2 · not yet recruiting
NCT07375563 — Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Ris · Phase 3 · recruiting
NCT07366801 — Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus H · Phase 2, PHASE3 · recruiting
NCT07232134 — The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia · Phase 3 · recruiting
NCT06587191 — Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03413306 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Last refreshed: 15 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03413306.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing